IHH Healthcare Withdraws IPO Plans for Indian Lab
By Ying Xian Wong
Malaysian hospital operator IHH Healthcare and other investors will withdraw plans for an initial public offering of Agilus Diagnostics in India, citing commercial considerations.
IHH said in a filing to the Malaysian bourse Wednesday that the IPO would be scrapped, which comes after it held talks with private-equity investors, indirect subsidiary Fortis Healthcare and Agilus. It added that Agilus, a unit of Fortis, could refile for an IPO in the future.
IHH didn't elaborate on the commercial reasons for the decision. It said the private-equity investors included the International Finance Corporation, NYLIM Jacob Ballas India Fund III and Resurgence PE Investments. Fortis had acted as promoter.
Agilus filed an IPO prospectus last September. The Gurgaon-based company operates a pathology laboratory network in India.
Write to Ying Xian Wong at yingxian.wong@wsj.com
(END) Dow Jones Newswires
February 14, 2024 01:14 ET (06:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst